FibroGen Announces Four Clinical Presentations on Roxadustat at Upcoming American Society of Nephrology Kidney Week 2018 Annual Meeting
16 oct. 2018 16h27 HE
|
FibroGen, Inc
Roxadustat Phase 3 Clinical Results in Late-Breaking Clinical Trial Posters and Oral Presentation SAN FRANCISCO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a leading...
FibroGen Reports Second Quarter 2018 Financial Results
07 août 2018 16h02 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Topline Clinical Data Readout on Track for Fourth Quarter of 2018 Feedback from FDA on Pamrevlumab Pivotal Programs in IPF and in Locally Advanced Unresectable Pancreatic...
FibroGen to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
01 août 2018 17h21 HE
|
FibroGen, Inc
SAN FRANCISCO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced that it will report second quarter 2018 financial results on Tuesday,...
FibroGen Announces Completion of Enrollment in U.S. Phase 3 Clinical Program for Roxadustat in Anemia Associated with Chronic Kidney Disease
07 juin 2018 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, June 07, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced the completion of patient enrollment in the Phase 3 studies supporting the...
FibroGen Reports Fourth Quarter and Full Year 2017 Financial Results
27 févr. 2018 16h11 HE
|
FibroGen, Inc
Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018 Pamrevlumab Phase 2 IPF Study Achieves Statistically Significant Attenuation of Lung Fibrosis as Measured...
FibroGen Reports Third Quarter 2017 Financial Results
08 nov. 2017 16h02 HE
|
FibroGen, Inc
Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...
FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)
18 oct. 2017 07h00 HE
|
FibroGen, Inc
SAN FRANCISCO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
About FibroGen, Inc.FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare Conference
13 juin 2017 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Chief Executive Officer Thomas B. Neff will participate...
FibroGen Reports First Quarter 2017 Financial Results
09 mai 2017 16h02 HE
|
FibroGen, Inc.
SAN FRANCISCO, May 09, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided...
FibroGen Announces China FDA Approval of CTA to Conduct Pivotal Phase 2/3 Clinical Trial of Roxadustat in Anemia Associated With Lower Risk MDS
31 mars 2017 07h05 HE
|
FibroGen, Inc.
SAN FRANCISCO, March 31, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced the approval by the China Food and Drug Administration...